❶Dear Employer, You have specified that you need a business plan.
Your business plan needs to be as detailed and through as possible. However, resist the urge to include every possible stitch of information in your plan. You will want to leave some content for your operational or marketing plans. When drafting your business plan: It is imperative that you never embellish things like sales or cashflow. When describing what your business does, or the types of products you sell, try not to be too technical. This is when you explore and explain the strengths, weaknesses, opportunities and threats to the overall success of your business.
Writing a business plan is not an easy feat. In fact, many business plans — especially for larger or more complex businesses — are several pages long and require ample research hours and solid planning skills. Truthfully, there are a number of resources available to those who need a little extra guidance in preparing or writing their business plan. You might choose to:. There are so many options available, and this is where our business writers step in to help. The key is to research what resources are available to you and determine how to best put them into action.
Hi there I am a professional business writer with over 7year of experience. I will create a business plan or proposal that would highlight your business, products, services and also sell your idea to your audience. I promise to deliver a high quality job,plagiarism free and on time. I definitely deliver what i promise. I am a professional business plan writer with the prior experience of writing many plans and would like to offer you my services.
Would you like to hire me? Hello, Hope you are doing great. Being a professional accountant and Finacial analyst I can prepare the best Business plan for you which will help you to achieve your target. Please send me a message then we can More. Dear Employer, You have specified that you need a business plan. I provide high-quality business plans that offer persuasive, accurate and informative for your audience, delivering quality results and representing you More. Dear Sir or Madam, Having a well written, well-presented business plan is essential for any new or expanding business, not only if you are seeking funding or other assistance, but because that business plan reflects More.
The email address is already associated with a Freelancer account. Enter your password below to link accounts: I forgot my password. Freelancer Jobs Accounting Need help with business plan Currently running a business, but needing help putting the actual business plan its self together. Looking to make some money?
If you are a small business owner who is struggling to write a business plan, help is here. Planning is one of the most important, yet often underestimated, parts of starting a business. In fact, many businesses fail from lack of research, goals and a thorough plan.
Why you need a business plan; Tips to collect the relevant information; The business plan outline; Creating a Business Plan – Where to Start. Before you even begin Googling phrases like 'help me write a business plan', you might be asking yourself why you even need a business plan to begin with. Business Analysis & Business Plans Projects for $20 - $ Currently running a business, but needing help putting the actual business plan its self together.
If you have a killer idea for a startup, but lack the time, resources and budget to develop a business plan, a business plan-generating app can help you get your plan on paper and, ideally, off the ground. Within the overall outline of the business plan, the executive summary will follow the title page. The summary should tell the reader what you want. This is very important.


text:
Nanoparticle-mediated therapeutic agent delivery for treating metastatic breast cancer—challenges and opportunities
Yunfei Li, Brock Humphries, Chengfeng Yang, Zhishan Wang
Markey Cancer Center / Cancer Research Priority Initiative
Breast cancer (BC) is the second leading cause of cancer-related death in American women and more than 90% of BC-related death is caused by metastatic BC (MBC). This review stresses the limited success of traditional therapies as well as the use of nanomedicine for treating MBC. Understanding the biological barriers of MBC that nanoparticle in vivo trafficking must overcome could provide valuable new insights for translating nanomedicine from the bench side to the bedside. A view about nanomedicine applied in BC therapy has been summarized with their present status, which is gaining attention in the clinically-applied landscape. The progressions of drug/gene delivery systems, especially the status of their preclinical or clinical trials, are also discussed. Here we highlight that the treatment of metastasis, in addition to the extensively described inhibition of primary tumor growth, is an indispensable requirement for nanomedicine. Along with more innovations in material chemistry and more progressions in biology, nanomedicine will constantly supply more exciting new approaches for targeted drug/gene delivery against MBC.
https://doi.org/10.3390/nano8060361
Acknowledgments: This work was supported in part by a Research Scholar Grant (RGS-15-026-01-CSM) from the American Cancer Society to C.Y. and a research grant from Elsa U. Pardee Foundation to Z.W.
© 2018 by the authors. Licensee MDPI, Basel, Switzerland.
Chemical Engineering (all)
Materials Science (all)
10.3390/nano8060361
Dive into the research topics of 'Nanoparticle-mediated therapeutic agent delivery for treating metastatic breast cancer—challenges and opportunities'. Together they form a unique fingerprint.
Nanomedicine Chemistry 100%
Breast Cancer Pharmacology, Toxicology and Pharmaceutical Science 30%
Gene Delivery Chemistry 30%
Drug Pharmacology, Toxicology and Pharmaceutical Science 20%
Death Pharmacology, Toxicology and Pharmaceutical Science 20%
Nanoparticle Chemistry 20%
Clinical Trial Chemistry 20%
Biological Product Pharmacology, Toxicology and Pharmaceutical Science 10%
Li, Y., Humphries, B., Yang, C., & Wang, Z. (2018). Nanoparticle-mediated therapeutic agent delivery for treating metastatic breast cancer—challenges and opportunities. Nanomaterials, 8(6), [361]. https://doi.org/10.3390/nano8060361
Li, Yunfei ; Humphries, Brock ; Yang, Chengfeng et al. / Nanoparticle-mediated therapeutic agent delivery for treating metastatic breast cancer—challenges and opportunities. In: Nanomaterials. 2018 ; Vol. 8, No. 6.
@article{b51d8ea1511041ec9a8dda21b882ca35,
title = "Nanoparticle-mediated therapeutic agent delivery for treating metastatic breast cancer—challenges and opportunities",
abstract = "Breast cancer (BC) is the second leading cause of cancer-related death in American women and more than 90% of BC-related death is caused by metastatic BC (MBC). This review stresses the limited success of traditional therapies as well as the use of nanomedicine for treating MBC. Understanding the biological barriers of MBC that nanoparticle in vivo trafficking must overcome could provide valuable new insights for translating nanomedicine from the bench side to the bedside. A view about nanomedicine applied in BC therapy has been summarized with their present status, which is gaining attention in the clinically-applied landscape. The progressions of drug/gene delivery systems, especially the status of their preclinical or clinical trials, are also discussed. Here we highlight that the treatment of metastasis, in addition to the extensively described inhibition of primary tumor growth, is an indispensable requirement for nanomedicine. Along with more innovations in material chemistry and more progressions in biology, nanomedicine will constantly supply more exciting new approaches for targeted drug/gene delivery against MBC.",
keywords = "Breast cancer, Metastasis, Nanomaterials, Nanomedicine",
author = "Yunfei Li and Brock Humphries and Chengfeng Yang and Zhishan Wang",
note = "Funding Information: Acknowledgments: This work was supported in part by a Research Scholar Grant (RGS-15-026-01-CSM) from the American Cancer Society to C.Y. and a research grant from Elsa U. Pardee Foundation to Z.W. Publisher Copyright: {\textcopyright} 2018 by the authors. Licensee MDPI, Basel, Switzerland.",
doi = "10.3390/nano8060361",
Li, Y, Humphries, B, Yang, C & Wang, Z 2018, 'Nanoparticle-mediated therapeutic agent delivery for treating metastatic breast cancer—challenges and opportunities', Nanomaterials, vol. 8, no. 6, 361. https://doi.org/10.3390/nano8060361
Nanoparticle-mediated therapeutic agent delivery for treating metastatic breast cancer—challenges and opportunities. / Li, Yunfei; Humphries, Brock; Yang, Chengfeng et al.
In: Nanomaterials, Vol. 8, No. 6, 361, 06.2018.
T1 - Nanoparticle-mediated therapeutic agent delivery for treating metastatic breast cancer—challenges and opportunities
AU - Li, Yunfei
AU - Humphries, Brock
AU - Yang, Chengfeng
AU - Wang, Zhishan
N1 - Funding Information: Acknowledgments: This work was supported in part by a Research Scholar Grant (RGS-15-026-01-CSM) from the American Cancer Society to C.Y. and a research grant from Elsa U. Pardee Foundation to Z.W. Publisher Copyright: © 2018 by the authors. Licensee MDPI, Basel, Switzerland.
N2 - Breast cancer (BC) is the second leading cause of cancer-related death in American women and more than 90% of BC-related death is caused by metastatic BC (MBC). This review stresses the limited success of traditional therapies as well as the use of nanomedicine for treating MBC. Understanding the biological barriers of MBC that nanoparticle in vivo trafficking must overcome could provide valuable new insights for translating nanomedicine from the bench side to the bedside. A view about nanomedicine applied in BC therapy has been summarized with their present status, which is gaining attention in the clinically-applied landscape. The progressions of drug/gene delivery systems, especially the status of their preclinical or clinical trials, are also discussed. Here we highlight that the treatment of metastasis, in addition to the extensively described inhibition of primary tumor growth, is an indispensable requirement for nanomedicine. Along with more innovations in material chemistry and more progressions in biology, nanomedicine will constantly supply more exciting new approaches for targeted drug/gene delivery against MBC.
AB - Breast cancer (BC) is the second leading cause of cancer-related death in American women and more than 90% of BC-related death is caused by metastatic BC (MBC). This review stresses the limited success of traditional therapies as well as the use of nanomedicine for treating MBC. Understanding the biological barriers of MBC that nanoparticle in vivo trafficking must overcome could provide valuable new insights for translating nanomedicine from the bench side to the bedside. A view about nanomedicine applied in BC therapy has been summarized with their present status, which is gaining attention in the clinically-applied landscape. The progressions of drug/gene delivery systems, especially the status of their preclinical or clinical trials, are also discussed. Here we highlight that the treatment of metastasis, in addition to the extensively described inhibition of primary tumor growth, is an indispensable requirement for nanomedicine. Along with more innovations in material chemistry and more progressions in biology, nanomedicine will constantly supply more exciting new approaches for targeted drug/gene delivery against MBC.
KW - Metastasis
KW - Nanomaterials
KW - Nanomedicine
U2 - 10.3390/nano8060361
DO - 10.3390/nano8060361
Li Y, Humphries B, Yang C, Wang Z. Nanoparticle-mediated therapeutic agent delivery for treating metastatic breast cancer—challenges and opportunities. Nanomaterials. 2018 Jun;8(6):361. doi: 10.3390/nano8060361

redpajama_set_name: RedPajamaCommonCrawl


Using the form below, you may upload your documents for printing or other services with Acro Photo Print Inc. If you have any further questions about how to use the form or our New York City legal printing services, please contact us.
1) Please fill in the form below to submit your file(s). Fields marked with * are required.
2) Click the "Add Files" button on the bottom of the upload window to select your files.
3) Click "Start Upload" once your file list is complete.
4) Once your files have been uploaded to the web-page click the "SUBMIT" button that appears.
Call us today at (929) 244-4322 to speak directly to a member of our team!


Kill the Parks. Kill 'Em All.
ABOUT 10,000 YEARS ago, some Indians found a sweet little piece of ground in the red-rock desert. They drew pictographs, snacked on antelope, and camped out a while but generally left the scenery intact. Centuries passed with little disturbance except for Manifest Destiny and the wind. Then, in 1929, President Hoover placed Utah's rock spires and delicate formations under government protection. That didn't change things too much: Even after the birth of the interstate highway system, only 127,000 people ventured into Arches National Monument in 1966. But in 1971, Congress voted to change Monument to Park, and within five years, annual traffic jumped to nearly 300,000. Today, it's at 860,000. The lesson? For any plot of earth worth loving, that four-letter word is a khaki-colored stake through the heart.
No, my beef is simple: Color it green on the road atlas and the expectation is that it will be, well, a park—a safe, manicured humanscape maintained for the enjoyment of people. Take the same piece of land, color it brown, and call it a national monument and visitorship is cut in half. Call it a wildlife refuge and another 50 percent won't bother to show up. The parks could use more money, but mostly they need to stop being, well, parks. That's right: Adios, Acadia. Sayonara, Saguaro.
The logic of national parks baffles me. We identify our most breathtaking, often endangered ecosystems for protection. We run environmental studies on them, catalog the wildlife, and elevate them incrementally through the gamut of designations before crowning them parks. Then the construction begins: Roads are cut and graded; 18,000-square-foot visitor centers are framed; stairs and railings emerge from cliffs and canyons. Soon, hotels and pancake houses bloom near the gates—or, worse, an entire neon tourist trap takes root, like Gatlinburg did at the edge of Great Smoky Mountains. It's only a matter of time before second-home owners are tazing wildlife on their morning jogs. Take note, all ye backers of schemes for Maine Woods and Mount Hood national parks: Do you really want go-cart tracks and a petting zoo on your doorstep?
But if designations are what have doomed our splendid vistas, they're also the solution. Let's ban new national parks and downgrade the ones we can still save from the creeping plague of mall-like visitor centers, boardwalks, and "scenic loops." Then rename the areas with more traditionally bureaucratic titles. Who would expect a paved campground at the Glacier National Frozen Precipitation Conservatory? Or the Rainier Extinct Volcano Near Seattle? I might be tempted to keep driving if I encountered signs for the Great Sand Dunes Deposited Silica Preserve. Try fitting that on a commemorative spoon.
The truth is, we love our parks, and we'll probably never get rid of the fancy hats and gift-shop shot glasses. They're as American as Twinkies. But we have to start managing them like what they are: highly sensitive ecosystems, not items on a checklist of RV destinations.
So what can you do? If you must visit the parks, then use them: Actually walk them instead of driving the loop. Give the superintendents reason to allocate more money for restoration instead of well-lit toilets and overflow parking. Better yet, seek out your own personal park that doesn't carry the label. There's plenty of public land as beautiful as, and less crowded than, official parks. Try an obscure refuge, national forest, or state park.
One of my favorite places is the 100,000-acre Valle Vidal, in northeastern New Mexico. It's designated a mixed-use area—and sure enough, the Japanese don't know about it. True, there's an occasional worn-out refrigerator dumped there and you'll sometimes find empty shotgun shells and beer cans. It could use more protection from loggers and drillers. But there are no visitor centers or hot-dog stands. And it gives me what the Grand Canyon and Yellowstone promise but can no longer deliver: solitude and nature in its raw form.


Join us for live music and art demonstrations from 5 to 8 p.m.! Updates will be available on our Final Friday Art Walks at our Facebook page or on our website at cedarcityartscouncil.org. The map associated with these events is below.


As a mutual insurance company, State Mutual does not have stockholders. The company is owned by and run for the benefit of its policyholders. The Company has assets in excess of $267 million, of which $29 million are surplus.
Download the 2018 report from Standard Analytical Service, Inc. here.


text:
Film Ireland
About Film Ireland
Posted on February 15, 2019 February 21, 2019 by Steven
Review: Alita, Battle Angel
DIR: Mike Mitchell • WRI: James Cameron, Laeta Kalogridis, Robert Rodriguez • PRO: James Cameron, Jon Landau • DOP: Bill Pope • ED: Stephen E. Rivkin, Ian Silverstein • DES: Caylah Eddleblute, Steve Joyner • MUS: Junkie XL • CAST: Rosa Salazar, Christoph Waltz, Jennifer Connelly, Mahershala Ali
The latest in a long line of attempts to turn Manga into gold arrives in the form of Alita, Battle Angel, courtesy of Robert Rodriguez directing and James Cameron serving as producer and co-writer. This has been a pet project of Cameron's for a long time, at one stage he was going to direct it himself. As a Rodriguez project, it has little or nothing that would make one think of his body of work. Except for maybe having one of the characters wear a bandana.
Alita's long gestation period has been explained as a mix of other commitments and waiting for technology to be advanced enough to do justice to the visuals of the story. For the most part this has been achieved. There are some good action scenes and beautiful visuals in place. Our motion-capture hero Alita, with her exceedingly large eyes, (looking like one of the children in those paintings our grandmothers owned) becomes easy on the sensibilities quickly enough. A sincere heartfelt performance from Rosa Salazar keeps her interesting and likeable throughout. She is probably the most successful character. Although that's hardly surprising as the rest of the cast are given little character time and simply serve as foil to the main protagonist.
But what's it about? Iron City, looking like a picturesque South American ghetto designed for a Coca Cola advertisement, is where the action takes place. Ido Dyson (no relation to the vacuum cleaner people), the local doctor of robotics (cyborg repairman to you and me), rummages through the scrapyard at the centre of Iron City. The scrap is provided by the sky city floating above, the last of its kind, a home to the elite, we are told, and the destination many people would like to get to. The only way to get there is with the right amount of dosh or if you become the champion of the local game Motorball. It involves roller skates and a ball and a violent temperament – and the locals love it. But back to the scrapyard; Ido finds a head amongst the scrap, brings it home and provides it with a body. Did I mention he just happens to fix cyborgs? Soon his new "daughter" has a name, Alita, and gets on with her new life as any enthusiastic young person might. She quickly falls in love with Hugo, a nice chap who happens to hijack cyborgs and steal parts from them. Ido has his own secret, which I will let you find out for yourself. As the story progresses, the life-embracing Alita continues to learn about herself and quickly becomes a young woman filled with a deeper understanding of her destiny. Meanwhile, others have become aware of her existence and aim to possess her.
This being a hoped-for franchise, Alita has the qualities of the first season of a television or web series. A more honest title for this would have been 'Alita Battle Angel, Chapter 1, We Hope'. Despite being overwrought with plot and events, it leaves us with as many questions as it answers. The muddled, episodic structure and speechmaking dialogue does not help. It's a shame that they spent so long waiting on the technology that they didn't take time to work more on the script.
Paul Farren
15A (see IFCO for details)
Alita, Battle Angel is released 15th February 2019
Alita, Battle Angel – Official Website
January 11, 2019 Review: Stan & Ollie
April 2, 2017 Review: Ghost in the Shell
August 22, 2016 Review: Lights Out
December 17, 2018 Review: Mortal Engines
May 13, 2016 Review: The Angry Birds
March 9, 2017 Review: Kong: Skull Island
July 7, 2017 Review: Spiderman: Homecoming
July 6, 2019 Review: Spider-Man: Far From Home
July 14, 2017 Review: War for the Planet of the Apes
October 25, 2019 Review: Little Monsters
CategoriesCinema Reviews, Reviews TagsAlita, Battle Angel, Paul Farren, Review
Previous PostPrevious Irish Film Institute 2019 Plans
Next PostNext Richard Waters, Director of 'In A Stranger's House'
A Celebration of the Life and Works of Ireland's Late Great Theatre & Film Actor and Comedian, Niall Tóibín @ Irish Cultural Centre Hammersmith London
Irish Film Review: Horrible Creature
Review: Uncut Gems
Arts and Disability Connect 2020
Get into Film: Training, Courses, Workshops & Masterclasses
Film Festivals 2020 – Here & Abroad
One Flew Over The Cuckoo's Nest – 45th Anniversary Screening @ First Fortnite
Áine Stapleton, director of 'Horrible Creature'
Catalyst International Film Festival – 2020
Submissions & Funding Deadlines
Irish Films to Look Out For in 2020
Dates for Your Diary: Upcoming Events of Interest
Film Ireland Podcast: Episode 39 – Farewell 2019!
Reviews of Irish Film @ Cork Film Festival 2019
Our Favourite Irish Films of 2019
2019: Contributors' Choice
Review of Irish Film @ Cork Film Festival 2019: The Other Lamb
Our Favourite Films of 2019
'The Wild Bunch' at 50
Review: Cats
Screen Ireland Funding for Third Quarter of 2019
Film Ireland Podcast: Episode 38 – Crime is Cool Kids
Review: Star Wars: The Rise of Skywalker
Review of Irish Film @ Cork Film Festival 2019: Screen Ireland World Premiere Shorts
Review of Irish Film @ Cork Film Festival 2019: Cork on Camera
Review of Irish Film @ Cork Film Festival 2019: Irish Shorts 5: It's No Longer A Journey Down The Road
Wayne Byrne, Author of 'Burt Reynolds on Screen'
Review of Irish Film @ Cork Film Festival 2019: Evening Redness of the South
Review: Frozen II
Review of Irish Film @ Cork Film Festival 2019: Floating Structures
Review: 'The Lighthouse' @ Cork Film Festival
Aoife Crehan, Writer/Director of 'The Last Right'
Review of Irish Film @ Cork Film Festival 2019: Lost Lives
Brian J. Falconer, Producer of 'Ordinary Love'
Irish Film Review: The Last Right
Review: Ordinary Love
Ruth Barton, Author of 'Irish Cinema in the Twenty-First Century'
Review of Irish Film @ Cork Film Festival 2019: The Yellow Bittern
Review of Irish Film @ Cork Film Festival 2019: The Last Right
Review: Portrait of a Lady on Fire @ Cork Film Festival
Gerard Mannix Flynn, Writer & Co-Director of 'Land Without God'
InConversation
InConversation with Louise Kiely
InConversation with Lenny Abrahamson
InConversation with Terry McMahon
Click for more>
Interview: Director Peter Foott, Actors Hilary Rose & PJ Gallagher, 'The Young Offenders'
Keep an eye out for notice of our new Film Ireland newsletter, coming soon.